TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: MD-R-2024-11-27-132697 | Pharmaceuticals and Healthcare
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Tumor Necrosis Factor Receptor Superfamily Member 18 Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET
7.1 GLOBAL TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 18 MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 Ablynx NV
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Amgen Inc
16.3 Apogenix GmbH
16.4 Bristol-Myers Squibb Company
16.5 Five Prime Therapeutics Inc
16.6 Incyte Corp
16.7 MedImmune LLC
16.8 Merck & Co Inc
16.9 Novartis AG
16.10 OncoMed Pharmaceuticals Inc
16.11 Regeneron Pharmaceuticals Inc
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TypeAMG-228
BMS-986156
FPA-154
GWN-323
INCAGN-1876
Others
By Application
Melanoma
Non-Small Cell Lung Cancer
Gastric Cancer
Blood Cancer
Others
Companies
Ablynx NV
Amgen Inc
Apogenix GmbH
Bristol-Myers Squibb Company
Five Prime Therapeutics Inc
Incyte Corp
MedImmune LLC
Merck & Co Inc
Novartis AG
OncoMed Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.